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Abstract: In the past decade, poly-γ-glutamic acid (γ-PGA)-based micro/nanoparticles have garnered 
remarkable attention as antimicrobial agents and for drug delivery, owing to their controlled and 
sustained-release properties, low toxicity, as well as biocompatibility with tissue and cells. γ-PGA 
is a naturally occurring biopolymer produced by several gram-positive bacteria that, due to its 
biodegradable, non-toxic and non-immunogenic properties, has been used successfully in the 
medical, food and wastewater industries. Moreover, its carboxylic group on the side chains can offer 
an attachment point to conjugate antimicrobial and various therapeutic agents, or to chemically 
modify the solubility of the biopolymer. The unique characteristics of γ-PGA have a promising 
future for medical and pharmaceutical applications. In the present review, the structure, properties 
and micro/nanoparticle preparation methods of γ-PGA and its derivatives are covered. Also, we 
have highlighted the impact of micro/nanoencapsulation or immobilisation of antimicrobial agents 
and various disease-related drugs on biodegradable γ-PGA micro/nanoparticles. 
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1. Introduction 
Nanoparticles (NPs) as drug delivery systems or direct anti-tumour systems facilitate unique 
approaches for many diseases. They have several benefits including: advances in detection, imaging, 
and delivering drugs to the site of infection. Liposomes, polymer-drug conjugates nanoparticles, 
polymeric nanoparticles and micelle nanoparticles are the most commonly used nanoparticles 
utilised in drug delivery systems [1,2]. Solid colloidal particles that are comprised of both 
nanocapsules and nanospheres are known as NPs. They are made through synthesis with preformed 
polymers and polymerisation methods [3,4]. The processes use minuscule droplets of liquid or solid 
materials that are coated with a polymeric material; this is known as nanoencapsulation. 
Nanocapsules are characterised by membrane-wall structures with an aqueous or oily core acting as 
a reservoir to contain the bioactive material (Figure 1). In contrast, nanospheres exhibit matrix 
systems where the bioactive material is dispersed throughout the particles [5]. The main characteristic 
feature of nanoparticles is their size, which can be 5–10 nm with 1000 nm as an upper size limit. 
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However, the range of use is usually 100–500 nm [6]. As emphasised by various authors, these 
nanoparticulated drug delivery systems are known for their great capacity as active vectors that can 
control and sustain the release of drugs at a site of localisation [4]. Their advantage of higher 
intracellular uptake over many other particulate systems is due to their subcellular size, and the 
ability to improve the stability of active substances [7]. They are also biocompatible with cells and 
tissue when made from materials that are biodegradable and biocompatible [8,9]. Moreover, 
nanoparticulated drug delivery systems have several other advantages over other drug delivery 
systems; this includes the fact that drugs can be incorporated without any chemical reactions, they 
stabilise drug activity, the drugs themselves are protected against degrading agents such as light and 
pH, there is a decrease in tissue irritation and high efficiency of drug encapsulation [10,11]. 
Researchers have extensively studied polymeric micro/nanoparticles as drug carriers in the field of 
pharmaceuticals [12–15]. Additionally, different researchers have published reviews on the 
mechanism of nanoparticle formation, the organisation of nanoparticulated systems and the 
preparation techniques of nanoparticles [6,15–18]. Nanoparticles that are biodegradable are usually 
used in the improvement of the therapeutical value of many water-insoluble and soluble drugs and 
molecules that are bioactive through the enhancement of solubility, bioavailability and retention time 
[19,20].  
 
Figure 1. The two main types of polymeric nanoparticles are nanocapsules (reservoir system) and 
nanospheres (matrix system) with different drug-loading materials.  
A very promising approach for developing nanomedicine is through the nanoencapsulation of 
the small molecules or the drugs in nanocarriers. This conventional drug entrapment technique gives 
efficient drug loading inside the nanocarriers, thus reducing the toxicity linked with the drugs. The 
nanocarrier targeting can enhance the effectiveness of the nanoencapsulated drug at the disease site 
[21]. The nanoparticle’s performance in vivo is usually influenced by surface chemistry, molecular 
weight and morphological characteristics. Nanoparticles that are surface modified have the property 
of being anti-adhesive through the extended arrangement of the particle surface. Acting as a steric 
barrier it decreases the degree of clearance by circulating macrophages of the liver and endorses the 
likelihood of undergoing improved permeation processes [19,20]. The release mechanism can be 
controlled through selection of the molecular weight of the polymer used. The higher the molecular 
weight of a polymer, the slower the in vitro drug will be released. Some of the problems challenged 
by new classes of active molecules can be solved by the careful design of delivery systems with 
respect to the route and target of administration [22]. Another application of nanoparticles is the 
directing of organs or tumours to increase their selective cellular internalisation and binding by 
receptor-mediated endocytosis. Targeting ligands are usually grafted to the nanoparticle’s surface 
via a linkage [23]. Moreover, confidence in nanotechnology success is high, given numerous 
applications including textiles, agriculture, fibre, forensic science, medical therapies and electronics 
[19,24]. 
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The most prevalent synthetic polymers for micro/nanoencapsulation are, poly (lactic-co-glycolic 
acid) (PLGA), poly(glycolic acid) (PGA) and poly(lactic acid) (PLA). They have all been approved by 
the US Food and Drug Administration (FDA) for particular medical applications, as they are 
biodegradable and are easily removed from the body in the form of water and carbon dioxide 
molecules [22,25]. However, these polymers may reduce the surrounding pH during polymer 
degradation, which subsequently affects cellular function by creating a highly acidic microenviroment, 
thus limiting their application in vivo [26]. Increased attention has turned to the use of biopolymers 
to overcome this problem. Naturally occurring biopolymers produced by living organisms during 
cell growth may be the key, as they can be produced in the laboratory and they show noticeable 
synthesising flexibility. One of the most recently discovered biopolymers for the application of 
nanoparticles is poly gamma glutamic acid (γ-PGA). Attention has been drawn to γ-PGA because it 
is biodegradable, biocompatible, non-toxic and non-immunogenic. Few reviews exist thus far that 
have explored γ-PGA designed nanoparticle drug delivery systems, which are used in many 
biomedical applications including vaccination, inflammation, cancer and other diseases [27–29]. In 
this review, the fabrication and characterisation techniques of γ-PGA nanoparticles and its 
derivatives are covered. In addition, we have highlighted the impact of nanoencapsulation and the 
immobilisation of various disease-related drugs with biodegradable γ-PGA nanoparticles. 
2. Poly-γ-Glutamic Acid (γ-PGA) as an Antimicrobial Coating and Drug Delivery System 
Naturally occurring poly-γ-glutamic acid (γ-PGA) is a biopolymer, which is biodegradable, 
water soluble, non-immunogenic and non-toxic for humans and the environment. It consists of 
monomer units of D-glutamic acid or L-glutamic acid or both. Glutamate is polymerised inside the 
cell through the γ-amide linkages. The polymer α-PGA is produced by chemical synthesis, while  
γ-PGA is produced microbiologically by a number of Bacillus species [27,29–32]. γ-PGA can be 
degraded in vivo to glutamic acid residues. The polymer is also secreted extracellularly as a free 
polymer into a fermentation medium, in fed-batch cultures. Bacillus licheniformis ATCC 9945a can 
produce γ-PGA with yields of more than 30 g/L. B. licheniformis and B. subtilis are characterised as 
safe microorganisms that, through cultivation, produce microbial γ-PGA [29,33,34]. Ashiuchi et al., 
2015 observed that γ-PGA ion-complexes (PGAICs) maintained surface antimicrobial activity. The 
complex of γ-PGA and a compound used in toothpaste called hexadecyl-pyridinium (HDP) is 
suitable as an anti-fungal agent due to its coating stability [35]. In order to control the release of bound 
and encapsulated drugs, in drug delivery applications, polymers of different molecular sizes are 
needed. Polydispersity and molecular weight determine the properties and applications of a polymer 
[4,36,37]. During chemical synthesis, the molecular weight of α-PGA can be controlled; γ-PGA’s 
molecular weight is dependent on the source of its production. Alkaline hydrolysis used to vary the 
molecular weight of microbial γ-PGA, other applications including ultrasonic degradation, microbial 
or enzymatic degradation and alteration of medium composition have also been tried [30,38,39].  
For nanoparticulate delivery systems, drugs are usually encapsulated in the nanoparticle’s 
polymer matrix or core. In recent years, there has been tremendous interest in polymeric 
nanoparticles for pharmaceutical and biomedical applications because of their in vivo 
biocompatibility, sub-micron size, and their precise and constant releasing properties [40,41]. The 
development of new biomaterials and their use as drug delivery carriers has resulted in the 
progression and alteration of new and current methods for the fabrication of nanoparticles. Attention 
has been drawn to γ-PGA because of its diverse properties, as already mentioned. Because of these 
properties, γ-PGA designed nanoparticles are used as drug delivery systems for many biomedical 
applications including cancer therapy, antimicrobial gene therapy, biological adhesives, vaccines and 
other applications [27,30]. 
2.1. Method of γ-PGA Nano/Microparticle Formulation 
Delivery systems are particulates designed for the regular release of pharmaceutical agents in 
order to maintain therapeutic drug levels for an appropriate period of time in the body. This is 
attained through the encapsulation of these therapeutic agents into a polymer particle that is 
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degradable, and the continuous release of the agent as the polymer matrix degrades [42,43]. Drug 
delivery systems (DDS) with nanoparticles are promising since they reduce toxic side effects and 
enhance the improvement of the desired therapeutic effect. The choice of NP preparation method is 
based on a number of factors such as the type of polymeric system, the area of application, size 
requirements, surface charge, molecular weight, hydrophobicity, hydrophilicity, biodegradability, 
biocompatibility and solubility of the drugs. For example, NPs that are produced for application in 
the medical field ideally should be totally free from additives or reactants [17,18]. Polymers that are 
block copolymers or self-assembled polymers have the ability to form nanostructures, that have been 
investigated in the fields of pharmaceuticals and biotechnology. Overall electrostatic forces, van der 
Waal forces, hydrophobic interactions, and hydrogen bonding are considered the key forces leading 
to the formation of the polymer [44,45]. There are a few γ-PGA-based nanoparticle preparation 
methods, and each differs in their organisation structure. The active molecule or a specific drug is 
usually included inside the centre of the nanocapsule, or it is absorbed into the matrix surface, of the 
nanosphere. The self-assembling polymer or block/graft copolymer method and the ionic gelation 
method are the most common methods for γ-PGA nanoparticle formulation [27]. To date, all of the 
formulated γ-PGA particle studies have been in nanoscale size, apart from three studies which 
investigated the fabrication of γ-PGA particles in micro scale size [46–48]. 
2.1.1. Solvent Exchange Method 
Nanoparticles that are made by the self-assembly of copolymers that are amphiphilic blocks or 
ones that are hydrophobically manipulated show success as drug carriers [49]. Generally, the 
copolymers made from hydrophilic or hydrophobic sections are able to form structures that are 
polymeric in aqueous solutions through hydrophobic interactions. These nanoparticles are made 
from inner hydrophobic moieties and outer hydrophilic shells [15,50]. Matsusaki et al., 2004 reported 
the first formation of bacterial γ-PGA nanoparticles [51]. They used γ-PGA as the hydrophobic 
backbone and L-phenylalanine (Phe) or L-leucine methyl esters (Leu) as the hydrophobic sections.  
L-phenylalanine or L-leucine methyl esters were grafted to γ-PGA in the presence of the water-soluble 
carbodimide (WSC) (Figure 2). These γ-PGA-Phe or γ-PGA-Leu copolymers with 30%–58% grafting 
degrees (determined by NMR) formed nanoparticles that were monodispersed in water because of 
their amphiphilic characteristics. 
 
Figure 2. Chemical structures of poly-γ-glutamic acid (γ-PGA) and γ-PGA hydrophobic derivatives 
achieved in the presence of water-soluble carbodimide (WSC), and the subsequent formation of self-
assembled nanoparticles (NPs). Adapted from Matsusaki et al., 2004 [51] and Piyapakom, 2014 [52].  
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In order to make self-assembled nanoparticles by the solvent exchange method, 10 mg/mL of γ-
PGA-Phe was dissolved in DMSO that was then added to the same amount of distilled water. The 
particles were then dialysed to remove DMSO and then lyophilised. The average size of the γ-PGA-
Phe NPs was approximately 200 nm, whereas γ-PGA-Leu NPs showed submicron order aggregations 
[51]. Kim et al., 2009 [53] found that the size of the γ-PGA-Phe formed monodispersed nanoparticles 
that can be easily controlled. By altering the NaCl concentration in distilled water, different NP sizes 
were obtained and ranged from 30 nm to 200 nm. Due to the ionisation of the carboxyl group found 
near to the γ-PGA surface, the nanoparticles showed highly negative charges, and the zeta potential 
was −25 mV. In the same study, it was shown that another hydrophobic amino acid L-tryptophan 
methylester (Trp) can be grafted to γ-PGA in order to form self-assembled nanoparticles. 
Nanoparticles were obtained using the precipitation and dialysis methods. However, the authors 
found that γ-PGA-Trp NPs could not be redispersed in phosphate buffer saline (PBS) after 
lyophilisation by freeze drying. All sizes of γ-PGA-Trp NPs aggregated and formed relatively large 
NPs when dispersed in PBS. In contrast, freeze-dried γ-PGA-Phe NPs redispersed well in PBS and 
the size distribution was the same as before lyophilisation. It is believed that the difference in 
dispersibility of freeze-dried γ-PGA NPs in PBS may be due to the difference in hydrophobicity 
between Trp and Phe. Moreover, the shape of γ-PGA-Trp NPs was more uniform and spherical than 
γ-PGA-Phe particles, yet γ-PGA-Trp NPs had a soft and flexible morphology. The size of particles 
ranged from 34 to 192 nm and 58 to 292 nm in γ-PGA-Phe NPs and γ-PGA-Trp NPs, respectively, 
depending on the increase in the concentration of NaCl. No evidence was found for the comparison 
of drug encapsulation efficiency and release profiles between γ-PGA-Phe NPs and γ-PGA-Trp NPs 
[53]. 
For drug encapsulation, γ-PGA loaded with protein nanoparticles were made, about 0.25–4 mg 
of bovine serum albumin was dissolved in 1 mL of saline buffer, followed by the addition of 1 mL of 
γ-PGA-Phe to the protein solution. Subsequently, the solution that resulted was centrifuged and 
rinsed constantly. Overall, the encapsulation of proteins with different molecular weights and 
isoelectric points into the nanoparticles was successful [54,55]. The efficiency of the encapsulation 
ranged between 30% to 60% in most samples. The encapsulation effectiveness for each protein was 
found not to be influenced by the protein’s physical properties. Moreover, the nanoparticle size 
increased when proteins were encapsulated within it. The increase for albumin, when it was 
encapsulated, increased the nanoparticle’s size, from 180 nm to 256 nm. This could be due to the 
swelling capacity increasing because of the hydrophilic properties of the proteins in the nanoparticles 
[27]. All the nanoparticles could be preserved through freeze-drying. The cytotoxicity test results for 
the nanoparticles have shown that they do not lead to cell damage. Furthermore, studies have proven 
that γ-PGA-Phe nanoparticles could have broad potential in the future as carriers with multiple 
functions for delivering drug and vaccines in biomedical and pharmaceutical applications [53,54]. 
However, the full properties of association are still not completely clear, and the protein-loaded 
structure requires further research. 
2.1.2. Ionic Gelation Method 
The ionic gelation technique uses surface-charge contact between a polymer and a 
polyanion/polycation or two oppositely charged polymers [56,57]. Lin et al., 2005 [58,59] used γ-PGA 
and Chitosan (CH) to form Polyion complex (PIC) particles in aqueous media (Figure 3). They found 
that different concentrations of CH (0.01%–0.2%) and γ-PGA produced smooth-surfaced and 
spherical nanoparticles of different zeta potentials and particle sizes (140–370 nm). Nanoparticles 
were made by the addition of negatively charged γ-PGA (160 kDa at pH 7.4) into positively charged 
CH (50 kDa at pH 6.0) under magnetic stirring. Using ultracentrifugation nanoparticles were then 
collected. Following the zeta potential, the particle size of the γ-PGA and CH nanoparticles were 
determined; mainly through the quantity of the γ-PGA concentration found in the solutions added 
to the concentration of CH in the surrounding media. When CH is at a fixed concentration, an increase 
in γ-PGA allows the γ-PGA molecules to interact with the CH, resulting in the formation of bigger 
nanoparticles. When the number of CH molecules are more than γ-PGA molecules, the extra CH 
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molecules are located on the surface of the γ-PGA-CH nanoparticle [58–60]. When a number of CH 
molecules exceeded that of local γ-PGA molecules, some of the excessive CH molecules were located 
on the γ-PGA-CH nanoparticle surfaces. The formed nanoparticles could have a neutral PIC core 
structure with a positively charged CH surrounding the shell in order to confirm colloidal balance. 
The research indicates that the nanoparticle size ranges from 80 nm to 400 nm with a surface charge 
ranging from −35 to +25 mV of γ-PGA-CH that can be controlled by altering the ratio of the mixture 
used in the two polymers [61]. 
 
Figure 3. Development of polyion complex (PIC) nanoparticles comprised of polyelectrolytes that are 
oppositely charged, giving electrostatic interactions. As shown, γ-PGA is the negatively charged 
polymer, while the positively charged polymer is Chitosan. 
In PIC nanoparticles, the key stability parameter is the pH and the ionic strength; this is due to 
the electrostatic interactions being influenced by the shielding of the ionic species [62]. Under 
physiological conditions, the weakening of the PIC limits their use as drug carriers. When the γ-PGA-
CH NPs are at pH 7.4, a deprotonation of the CH occurred, which led to the collapse or aggregation 
of nanoparticles. The nanoparticles that remained were in the range of pH at 2.5–6.6. To overcome 
this, nanoparticles that are multi-ion-cross-linked were made with γ-PGA and CH mixed with 
Tripolyphosphate (TTP) and MgSO4, and they showed significant increases regarding their stability 
[63]. These cross-linked nanoparticles have a greater constancy over a wider pH range than the 
nanoparticles that are uncross-linked [27]; in order to increase the microparticle’s stability in a very 
broad range of pH, this was done through the use of magnesium sulfate and the TTP. They were 
utilised for the physical linking of γ-PGA to CH by ionic gelation which is being used increasingly in 
the field of biomedical science. 
2.2. Nanoparticle Characterisation Techniques 
To understand the properties before developing them for additional medical application, 
nanoparticle characterisation is vital (Figure 4). The size of nanoparticles is very important for several 
reasons: to determine the degradation rate, the release profile and to establish the effectiveness of the 
therapeutic agent with regard to cellular uptake and tissue penetration [64]. The size distribution, 
morphology and particle size are determined by scanning electron microscopy (SEM), transmission 
electron microscopy (TEM), atomic force microscopy (AFM) or mainly by dynamic light scattering 
(DLS) based on photon correlation spectroscopy [65,66]. The physical form of the polymer and the 
drug must be known, as this will influence the in vivo and in vitro drug release properties. 
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Nanoparticles’ longevity and intracellular trafficking of particles as a function of pH and 
mucoadhesion are all affected by the zeta potential. Furthermore, the nanoparticle distribution in the 
body following administration is determined by hydrophobicity. Hydrophilic particles tend to stay 
in the blood for a lengthier time [66–68]. A Zetasizer is widely used to determine the zeta potential. 
The zeta potential results can be negative or positive, and they are determined by the type of polymer 
or the materials used for surface modification. This method is commonly employed to identify the 
nanoparticle’s surface charges [46,69]. In addition, hydrophilicity and hydrophobicity are determined 
via the corresponding hydrophobic interaction chromatography (HIC) or water contact angle 
measurements [70]. NPs which are usually used for drug delivery in an amorphous phase are more 
preferable than the crystalline phase, as the last is not accessible in general. The crystallinity of NPs 
is determined by X-ray diffraction (XRD) [71]. The encapsulation efficiency, degradation rate and 
nanoparticle size of the polymer are influenced by the molecular weight of the polymer. Polymer 
chain length is correlated with the molecular weight, where the higher the molecular weight, the 
longer the length of the chain. Additionally, the length of the chain reveals the lipophilicity or 
hydrophilicity of the polymer. When the chain length is increased, it decreases the degradation rate 
of the polymer and raises its lipophilicity. Thus, through varying its molecular weight, the 
degradation rate of the polymer and the kinetic release of the drug can be controlled. Size exclusion 
chromatography usually determines molecular weight [41,72,73]. 
 
Figure 4. Essential techniques for nanoparticles (NPs) characterisation; SEM: scanning electron 
microscopy; TEM: transmission electron microscopy; AFM: atomic force microscopy; DLS: dynamic 
light scattering; XDR: X-ray diffraction; HIC: hydrophobic interaction chromatography.  
3. Medical Applications of γ-PGA-Based Micro/Nanoparticles 
The polymer γ-PGA is expected to be a useful material-drug conjugate in the future. 
Nanoparticles made from natural or artificial polymers have applications in many biomedical and 
technological fields because of their surface functionalities, chemical structures and their controlled 
size. Nanoparticles containing therapeutic agents that have been entrapped successfully include 
peptides, proteins and various small molecules previously discovered to have major potential as drug 
delivery systems [74,75]. Here, we are detailing the use of γ-PGA-based micro/nanoparticles as a 
delivery vector to treat different diseases. Table 1 displays the summary of γ-PGA-based 
micro/nanoparticles drug delivery applications with particle size and encapsulation efficiency (EE%). 
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Table 1. Poly-γ-glutamic acid (γ-PGA)-based micro/nanoparticles drug delivery applications. 
Drug Loaded in PGA  
Micro/Nanoparticles 
Applications Size (nm) EE% Reference 
Adjuvant Japanese encephalitis virus vaccine 200 - [76] 
Antigen Vaccine development 150–300 55–60 [49,53,54,77–83] 
DNA Gene therapy 130–204 94–99 [84,85] 
Doxorubicin Antineoplastic therapy 150–630 51–69 [86] 
Erythromycin Antimicrobial therapy 220–280 43–80 [87] 
Fibroblast growth factor and heparin Human foreskin fibroblast cells 206–272 85–97 [88] 
Insulin (oral) Diabetes therapy 241–6120 44–73 [89–92] 
Lansoprazole Gastroesophageal reflux disease 342–367 μm 75–92 [47] 
Paclitaxel Liver cancers 128 50–53 [93] 
Peptides (LL-37) and nitric oxide Antimicrobial therapy 793–2128 13–76 [46] 
Proteins such as ovalbumin Tumour vaccines 250 55–60 [94,95] 
RNA Gene Therapy 216 - [96] 
Saquinavir Antiretroviral therapy 188–307 77 [97] 
3.1. Antimicrobial Therapy 
Antimicrobial peptides (AMPs) are promising antibiotics as they present a wide range of 
antimicrobial activity against gram-negative and gram-positive bacteria, parasites, enveloped viruses 
and fungi. These antibiotics simply do not induce resistance (in contrast to other antibiotics). These 
peptides are the only human peptides from the cathelicidin family that present high antibacterial 
activities; this is due to the biological properties the molecule possesses. Many studies involving the 
AMP encapsulation and biopolymer immobilisation led to improving the active agent’s release [98]. 
High concentrations of the peptide for an extended time period should be maintained to achieve 
optimal therapeutic effects sufficiently. For this, Sun et al., 2015 revealed a novel microencapsulation 
system loaded with AMPs made from poly-γ-glutamic acid and CH and prepared through the ionic 
gelation process [46]. 
A study by Hoennscheidt et al., 2013 [99] has found that the drug quinine was encapsulated 
partially with γ-PGA of a high molecular weight made from B. licheniformis. This drug (Quinine) is 
known to be the most popular anti-malarial drug linked with very severe side effects when 
overdosed. This drug is not effectively water-soluble; it works in a prototypical manner to many 
hydrophobic drugs. Steady distributions were made through the use of a technique based on solvent 
evaporation and other characteristics [99]. For acquired immunodeficiency syndrome (AIDS) 
treatment, the drug Saquinavir (SQV) is used as a protease inhibitor. However, it has disadvantages, 
including low permeability through the blood-brain barrier in clinical practice [100]. Usually, the 
blood-brain barrier has a high transendothelial resistance to many substances such as the 
antiretroviral drugs from entering the brain through the paracellular route [101]; this makes 
transcellular transport the main pathway for the delivery of SQV to the central nervous system. Brain 
microvascular endothelial cells are the major component of the blood-brain barrier; they have sialic 
acid residues of glycoproteins which are acidic thus aiding in the production of an anionic domain 
on the luminal front of the cell. These endothelial cells have the ability to attract entities that are 
positively charged, through electrostatic interaction and the use of conjugation and cationic colloids 
has led to the enhancement of the effectiveness of antiretroviral SQV and endocytosis [100,101]. 
Kuo et al., 2011 [100,102] conducted a study that aimed at developing nanoparticles made with 
SQV-polylactide-co-glycolide (PLGA) at the core of the nanoparticle and γ-PGA and 
Polyethyleneimine (PEI) on the surface which was used as a system for drug delivery. The 
hydrophobic PLGA nanoparticles can spread and aid the dissolution properties of SQV from the 
PEI/γ-PGA/SQV-PLGA nanoparticles through the hydrophilic γ-PGA and the grafted PEI charge. 
The study investigated the size distribution, the morphology of the particle and the efficiency of the 
PEI grafting in addition to the effectiveness of the entrapment of the SQV and the release of SQV 
kinetics. To release and encapsulate SQV, the PEI/γ-PGA/SQV-PLGA nanoparticles were produced. 
The entrapment efficiency of the SQV could be improved by using SQV at low concentrations. 
Moreover, PEI at a high concentration delayed the employment of free PEI on to the surface medium 
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of γ-PGA/SQV-PLGA nanoparticles. PEI at high grafting competence causes the underdevelopment 
of SQV from the PEI/γ-PGA/SQV-PLGA nanoparticles [100,102].  
3.2. Cancer Therapy 
Cancer is one of the most lethal diseases and the chemotherapy used to treat it is known to be 
very toxic towards healthy tissues. The most recognised and used anticancer drugs are known to 
have a short half-life in plasma with limited solubility in aqueous conditions, which reduces their 
efficiency as therapeutic drugs [93,103]. A study was developed by Liang et al., 2006 [93] on the 
formulation of poly (γ-glutamic acid)-poly (lactide) nanoparticles filled with paclitaxel in order to 
treat liver cancer. Paclitaxel is commonly used to treat breast and ovarian cancer; however, it can also 
be used with many other types of cancer as many cancer cells such as hepatoma cells are killed when 
exposed to this drug [93,104]. To target liver cancer cells, the group introduced glucosamine to 
Paclitaxel-loaded nanoparticles conjugated to the carboxyl (–COO–) groups on γ-PGA to work as a 
moiety. Asialoglycoprotein receptors found on the surface of hepatoma cells enables them to 
recognise the N- and the galactose acetylgalactosamine-terminated glycoproteins (ASGP). The 
formulated particles used were about 128 nm with a zeta potential of 19.6 mV. The study concluded 
that the complexes have the ability to target hepatoma tumour sites through the ASGP receptor-
affected recognition, leading to a reduction in tumour size. Therefore, they are capable of being used 
as a system for drug delivery to both liver cancers and other liver conditions [104]. 
Cancer drugs are usually directed into the body as intravenous infusions that may cause a burst-
like release and decay of the drug concentration in the blood. Successfully sustained drug release 
formulations have shown that long-term exposure of ailing tissues to a reasonable drug concentration 
is more useful and better than a higher concentration of the drug [28]. Manocha and Margaritis, 2010 
[28] have successfully made an ionic complex NP containing Doxorubicin/γ-PGA. Doxorubicin 
(DOX) is an anthracycline antibiotic commonly used as an antineoplastic mediator; the association of 
DOX on nanoparticles was shown to have controlled release over an extended period of time, 
therefore increasing its effectiveness and also reducing the toxic side effects that come with it. The 
carboxyl groups offer an attachment point for the chemotherapeutic drugs to the γ-PGA carrier 
[85,105]. The study aimed to investigate the use of the carboxyl group with the γ-PGA polymer, in 
order to optimise the formation of ionic complexes with anticancer cationic drugs. The specific 
connections between DOX and γ-PGA, to produce robust ionic complexes, were also investigated. It 
was found that carboxyl groups have the ability to produce strong ionic connections with the selected 
drugs because they are great hydrogen bond donors. The finding may act to help provide a new drug 
carrier for the controlled release of DOX in malignant tissues. The particle size was between 80 to 86 
nm with a zeta potential of −30 to −56 mV [86]. 
Another study, Matsuo et al., 2010 [80] discovered that γ-PGA NPs are excellent delivery carriers 
for antigens and for stimulate production of antigen-loaded dendritic cells (DCs) used in many cancer 
immunotherapies. Vaccine systems based on dendritic cells through the use of γ-PGA NPs as a 
delivery system for antigen carriers appear to have many applications in the design of vaccines aimed 
to trigger the responses of T cells, helpful in cancer therapy and developing chronic viral disease 
vaccines [80]. 
3.3. Gene Therapy 
In gene therapy, there are three different methods applied for gene delivery. The first one is the 
use of naked DNA, at high levels of gene expression, by the direct injection of free DNA to the infected 
site. This appears to be suitable for treating tumour sites that are readily available by direct injection, 
like skin and muscles, but it is unsuitable for a systemic delivery. The second approach involves using 
genetically altered viruses. These viruses in viral vectors have the ability to transfer their genetic 
materials into the host cells [106]. The third method of delivery is the use of non-viral vectors that 
have a cationic nature, provided by cationic polymers or cationic lipids. They interact with DNA 
through electrostatic interactions, as DNA is negatively charged, leading to the formation of 
polyplexes and lipoplexes, respectively [107]. 
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Currently the most important approach in gene therapy via a systemic pathway is the 
development of non-toxic gene vectors that are stable, that can easily encapsulate and that are capable 
of treating specific cell types such as cancerous cells by delivering foreign genetic materials [107]. Yet 
complexes based on NPs lead to many problems regarding the release of DNA when it arrives at the 
required site, making its transfection efficiency rather limited. In order to develop effective vectors 
to be used for DNA transfection, knowledge of the internalisation mechanism is vital. To solve this, 
a study carried out by Peng et al., 2009 [85] developed and modified the internal structure of 
CH/DNA complexes through the incorporation of negatively charged γ-PGA. The possible 
internalisation mechanism of CH/DNA/γ-PGA complexes was investigated through the use of 
transmission electron microscopy and the inhibitors specific to different endocytic pathways [85]. 
Complexes of CH/DNA were taken up by pathways mediated by micropinocytosis and caveolae 
(sub-microscopic plasma membrane pits that are available in many mammalian cells). Both pathways 
were enhanced through the incorporation of γ-PGA in the DNA/CH complex, yet the caveolae-
mediated pathway played the most important role. Following internalisation, the amount of 
CH/DNA/γ-PGA entering the lysosomes was less than that CH/DNA alone, which led to enhanced 
expression at the gene level [85]. 
High-specificity Small Interfering RNAs (siRNAs) are known to silence target genes; they 
therefore have the potential of being a new strategy to provide therapeutic drugs that lower 
unwanted gene expression. Yet there are many disadvantages concerning the use of siRNA for 
therapy, including degradation in the intracellular cytosol and plasma, leading to a shorter half-life. 
Moreover, the internalising of naked siRNAs cannot be done efficiently inside cells [108]. A carrier 
system based on CH with the addition of γ-PGA for a siRNA delivery was conducted by Liao et al., 
2010 [96]. The results obtained from this study revealed that γ-PGA has a vital role in the 
enhancement of the cellular uptake of CH complexes: providing increased siRNA release, leading to 
an improvement in gene silencing and extending the therapy’s duration. Combining the complexes 
of CH, siRNA and γ-PGA presents an innovative method that can be used as a proficient siRNA 
transfection vector [96]. 
3.4. Diabetes Therapy 
Drugs being administrated orally are preferable since it is painless and straightforward. 
Medication that is orally administrated would be particularly valuable in the management of many 
diseases, especially chronic ones like diabetes that need medication over a lifetime [109,110]. There 
are many issues regarding patient compliance, because of the inconvenience of injections on a daily 
basis in addition to the insulin therapy that is given by a subcutaneous injection. Thus orally 
administrated insulin is better as it enters the portal circulation where it goes via the liver before it 
reaches systemic circulation, allowing it to resemble the insulin secreted physiologically, in 
comparison to the well-known conventional administration by subcutaneous procedures that may 
lead to peripheral hyperinsulinemia [63,89]. Oral insulin administration will, therefore, benefit 
patients greatly. However, in the gastrointestinal (GI) tract, insulin is known to be inherently unstable 
as it has a low penetrability for intestinal epithelium [111,112]. In order to provide an effective insulin 
delivery system, nanoparticles should have balanced characteristics; including their size, which 
needs to be large enough to carry insulin but also small enough to permit uptake and diffusion. 
Mucoadhesion extends the housing time of nanoparticles during their absorption, although it can 
cause a delay in their diffusion through the mucous layer of the GI tract. Many nanoparticle 
formulations have been presented and tested, many of which have been modified in order to find the 
exact configuration so that they can be used for oral insulin delivery [112]. 
Several studies formulated an insulin delivery system composed of CH/γ-PGA nanoparticles 
[89–92]. These NPs were sensitive to pH, which led to an insulin absorption increase in the intestine, 
as the γ-PGA NPs increased the insulin residence time in the small intestine, which led it to infiltrate 
better into the mucus layer, and then mediate the transient opening of the junction between 
enterocytes where the insulin was released by the pH sensitive NPs. In diabetic rats the results 
showed moderate, extended hypoglycemia with a bioavailability of about 15%; however, this 
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increased to 20% when the nanoparticles were enteric-coated capsules. Nanoparticles that are cross-
linked with multi-ions were formed when γ-PGA was mixed with CH, MgSO4 and tripolyphosphate. 
Such complexes are considered to be stable and more compact over a range of pH values, in addition 
to being more effective in insulin transport than simple nanoparticles. Insulin being transported 
through the use of CH γ-PGA nanoparticles was shown to be an effective alternative to the usual 
application of subcutaneous basal-acting insulin [90]. 
The study presented by Sonaje et al., 2010 [89] discussed the use of nanoparticles that are pH 
sensitive, with γ-PGA/CH shielding providing an oral administration system for insulin through a 
paracellular pathway. Chitosan can adhere to the surface of epithelial cells, leading to the transient 
openings in the junctions of contiguous cells [89]. The study also reported the use of enteric-coated 
capsules with the freeze-dried nanoparticles to be used for the oral delivery of insulin. The main idea 
of the enteric-coated capsule is for it to remain intact in the stomach, within an acidic environment 
and to begin dissolving when it reaches the small intestine, which has a neutral environment. This 
encapsulation may lead to the prevention of the disintegration of the nanoparticles in the stomach, 
thereby leading to an increase in the overall number of nanoparticles being presented to the small 
intestine, consequently increasing the bioavailability of insulin [89].  
3.5. Vaccine Therapy 
Vaccines are used as an active device in the modulation of host immune responses to target a 
specific antigen, particularly microbial and pathogen-associated antigens [113]. The immunogenicity 
of vaccines is enhanced by the use of adjuvants through the use of various methods. Without the 
utilisation of an adjuvant, the effective immune response induced by a vaccine often fails. Many 
studies are in place to evaluate the vaccine adjuvant and antigen delivery systems based on particles, 
designed to achieve very effective immune responses [114]. Nanoparticles made from poly-γ-
glutamic acid and L-phenylalanine ethyl ester have resulted in cellular and humoral immune 
responses that are antigen-specific for a wide range of antigens. γ-PGA nanoparticles may exhibit 
more significant antigen-specific adaptive responses in laboratory animals than simple antigens or 
antigens mixed with additional adjuvants. γ-PGA nanoparticles carrying antigens have led to 
effective anticancer and antiviral immunity, demonstrating fully their importance as capable vaccine 
delivery system [83]. 
A study conducted by Uto et al., 2013 [83] revealed that γ-PGA nanoparticles serve as antigen 
carriers, endorse dendritic cell maturation and encourage the presentation of antigens through class 
I major histocompatibility compex (MHC) molecules. Such nanoparticles stimulate rapid antigen-
specific cluster of differentiation 8 (CD8) T cell activation. γ-PGA nanoparticles efficiently provoke 
an adaptive immune response by dendritic cell arbitrated in in vivo immunity, which could lead to 
them being used as antigen delivery systems [83]. 
These authors developed an efficient single-dose immunisation procedure through the 
administering of Japanese encephalitis virus-like particles (JE-VLP) with γ-PGA nanoparticles. They 
showed that specific cell-mediated and humoral immune reactions associated with JEV were 
improved through the addition of adjuvants. When injected into a mouse, the γ-PGA nanoparticles 
did not provoke any injury to the tissue or penetrate inflammatory cells. Moreover, they did not lead 
to any acute toxicity of the cells. Using a two-dose procedure, the γ-PGA nanoparticles were directed 
into the mouse, where they did not lead to any anti-γ-PGA nanoparticle immune responses [76]. 
Overall, the study showed that one dose of JE-VLP combined with γ-PGA nanoparticles provoked 
antibodies that are JE-specific, thereby enhancing defence responses against the virus. Based on this 
study, the third generation of JE vaccines are to be designed and could be used on military workers 
and travellers [76]. The outcome of such studies is awaited with great interest. 
3.6. Gastroesophageal Reflux Disease (GERD) 
Lansoprazole sodium works as a proton pump inhibitor which decreases the secretion of gastric 
acid. With decreasing pH, the degradation rate and the instability of lansoprazole is increased [47]. 
In the stomach, the degradation of lansoprazole occurs because of to the acidic environment, leading 
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to a reduction in clinical effect and bioavailability. However, lansoprazole microparticles within 
enteric capsules display better absorption characteristics than enteric tablets. A microparticle method 
made from poly glutamic acid and chitosan was established for oral lansoprazole delivery through 
the use of an ionic gelation method. In the GI tract, the pH environment is different, as the stomach 
has an acidic environment and the small intestine has an alkaline environment. In order to increase 
the stability of microparticles, a compact structure of carriers was developed to work in a wider range 
of pH, sodium tripolyphosphate and magnesium were introduced to crosslink CH physically with 
γ-PGA in such investigations [47,89,90]. 
The TTP and the sulphate salts are routinely cross-linked via ionic gelation in many biomedical 
applications. The FDA have recognised sodium tripolyphosphate as a food additive. Between 
carboxylate ions on γ-PGA and Mg2+ ions, physical gelation might occur through electrostatic 
interactions. The most abundant ion in living cells is Mg2+. Singh et al., 2012 [47] prepared 
microparticles that are pH-sensitive, and subsequently complexed with CH, TTP and MgSO4, and 
utilised with γ-PGA in different ratios. The research concluded that microparticles are free flowing 
with a round shape; many chitosan properties were altered with the addition of γ-PGA, leaving γ-
PGA-CH micro/nanoparticles, a very useful drug delivery application carrier. Acid-dependent drugs, 
including lansoprazole, can now be expressed in the form of an enteric covered capsule with 
chitosan/γ-poly-glutamic acid microparticles in them, used as a continued drug release delivery 
method [47,89,90]. 
4. Conclusions 
Delivering macromolecules and small molecular weight drugs for localised or targeted delivery 
to specific sites has been a challenging task in the past. The development, improvement and advances 
in nanotechnology-based drug delivery systems have offered appropriate new solutions for this kind 
of application. Poly-γ-glutamic acid (γ-PGA) is a very promising non-toxic, non-immunogenic and 
biodegradable polymer that can be produced naturally by various strains of Bacillus. Different roles 
of γ-PGA such as a biocontrol agent, cryoprotectant, probiotic protectant, bacteriophage protectant 
or thickeners have been reported. This review is meant to contribute to the understanding of γ-PGA 
nanoparticles’ (NPs) methods of fabrication and trace the development of γ-PGA nanoparticles and 
their medical applications in treating different diseases. Techniques such as ionic gelation are 
straightforward and do not involve any organic solvents, harsh chemicals or mechanical treatments. 
Using fermentation techniques, γ-PGA can be produced simply and extracellularly with high yields. 
Using nanoparticles as drug delivery systems based on nanoparticle γ-PGA, as  detailed in this 
review, leads to the prediction that they will be crucial in the future due to their unique properties 
and safety features. However, the detailed characterisation of the in vivo performances of these well-
designed nanoparticles is lacking. More systematic studies must be performed to regulate the 
performance and consistency of these nanoparticles in the blood or lymphatic fluids. Much more in-
depth study is vital for understanding the details of how drugs are released when γ-PGA-based 
nanoparticle vectors enter target cells. 
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